Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
Remsima
Description:
A biosimilar medicine containing infliximab, a monoclonal antibody used to treat inflammatory and autoimmune diseases.
Primary topic:
Biosimilars and Bioanalytical Methods (61%)
Related topics:
Biosimilars and Bioanalytical Methods (61%),
Inflammatory Bowel Disease (22%)
OpenAlex ID:
keywords/remsima
Physicochemical characterization of Remsima®
2014
·
Soon Kwan Jung
, Kyoung Hoon Lee
, et al.
·
mAbs
·
365
Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima
2015
·
Shomron Ben-Horin
, Miri Yavzori
, et al.
·
Gut
·
191
The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
2015
·
Ashok Jha
, Alex Upton
, et al.
·
Advances in Therapy
·
171
PDF
Approval of the first biosimilar antibodies in Europe: A major landmark for the biopharmaceutical industry
2013
·
Alain Beck
, Janice M. Reichert
·
mAbs
·
148
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
2015
·
J. Sieczkowska
, D. Jarzębicka
, et al.
·
Journal of Crohn s and Colitis
·
146
Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study
2015
·
Jørgen Jahnsen
, Trond Espen Detlie
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
116
PDF
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
2015
·
Sang Hyoung Park
, Young-Ho Kim
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
116
PDF
Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study
2016
·
Lydia C. T. Buer
, Bjørn A. Moum
, et al.
·
Journal of Crohn s and Colitis
·
96
PDF
Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
2019
·
Smriti Subedi
, Yu Gong
, et al.
·
Drug Design Development and Therapy
·
94
PDF
A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima
2017
·
Karthik Pisupati
, Yuwei Tian
, et al.
·
Analytical Chemistry
·
89
Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars
2016
·
M Begoña Ruiz-Argüello
, Ainara Maguregui
, et al.
·
Annals of the Rheumatic Diseases
·
82
Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis
2016
·
Radan Keil
, Martin Wasserbauer
, et al.
·
Scandinavian Journal of Gastroenterology
·
65
Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™
2017
·
Karthik Pisupati
, Alexander Benet
, et al.
·
mAbs
·
63
PDF
Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
2017
·
Changsoo Lee
, Min Jeong
, et al.
·
mAbs
·
62
PDF
Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre
2017
·
M. Kolar
, D. Duricova
, et al.
·
Digestive Diseases
·
53
The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
2016
·
Paolo Dapavo
, Igor Vujic
, et al.
·
Journal of the American Academy of Dermatology
·
49
Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation
2014
·
Bradley J. Scott
, Agnes V. Klein
, et al.
·
The Journal of Clinical Pharmacology
·
43
Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease
2015
·
Karin Malíčková
, Dana Ďuricová
, et al.
·
Biologicals
·
36
Biosimilar infliximab use in paediatric IBD
2017
·
Lisa Richmond
, Lee Curtis
, et al.
·
Archives of Disease in Childhood
·
35
PDF
Experience with Biosimilar Infliximab (Remsima®) in Norway
2017
·
Jørgen Jahnsen
, Kristin Kaasen Jørgensen
·
Digestive Diseases
·
35
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
2016
·
Jørgen Jahnsen
·
Therapeutic Advances in Gastroenterology
·
31
PDF
Long‐term efficacy and safety of CT‐P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
2019
·
Nam Hee Kim
, Ji Hyun Lee
, et al.
·
Journal of Gastroenterology and Hepatology
·
30
One-month stability study of a biosimilar of infliximab (Remsima®) after dilution and storage at 4 °C and 25 °C
2016
·
V. Vieillard
, A. Astier
, et al.
·
Annales Pharmaceutiques Françaises
·
22
The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13
2015
·
Walter Reinisch
, Edouard Louis
, et al.
·
Expert Review of Gastroenterology & Hepatology
·
22
PDF
Progress in Biosimilar Monoclonal Antibody Development: the Infliximab Biosimilar Ct-P13 in the Treatment of Rheumatic Diseases
2015
·
Jürgen Braun
, Alex Kudrin
·
Immunotherapy
·
22
Show more works
View as search
Works count:
144
Citation count:
2,496
Year
Topic
Type